MRD and Clinical Response Predictors of PFS in CLL

Summary

In chronic lymphocytic leukemia, progression-free survival in minimal residual disease–negative patients can be best predicted using a combination of minimal residual disease and the clinical response. The combination is more accurate than clinical response alone. Assessment using only splenomegaly has no influence on progression-free survival prediction.

  • progression-free survival
  • peripheral blood
  • prediction
  • fludarabine
  • cyclophosphamide
  • rituximab
  • bendamustine
View Full Text